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ABSTRACT
Multiple myeloma is a plasma cell malignancy, which develops in the bone marrow and frequently leads to severe bone
destruction. Current antiresorptive therapies to treat the bone disease do little to repair damaged bone; therefore, new
treatment strategies incorporating bone anabolic therapies are urgently required. We hypothesized that combination therapy
using the standard of care antiresorptive zoledronic acid (Zol) with a bone anabolic (anti-TGFb/1D11) would be more effective at
treating myeloma-induced bone disease than Zol therapy alone. JJN3 myeloma-bearing mice (n¼ 8/group) treated with
combined Zol and 1D11 resulted in a 48% increase (p 0.001) in trabecular bone volume (BV/TV) compared with Zol alone and a
65% increase (p 0.0001) compared with 1D11 alone. Our most signiﬁcant ﬁnding was the substantial repair of U266-induced
osteolytic bone lesions with combination therapy (n¼ 8/group), which resulted in a signiﬁcant reduction in lesion area
compared with vehicle (p 0.01) or Zol alone (p 0.01). These results demonstrate that combined antiresorptive and bone
anabolic therapy is signiﬁcantly more effective at preventing myeloma-induced bone disease than Zol alone. Furthermore, we
demonstrate that combined therapy is able to repair established myelomatous bone lesions. This is a highly translational
strategy that could signiﬁcantly improve bone outcomes and quality of life for patients with myeloma. © 2018 The Authors.
Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Multiple myeloma is a cancer of plasma cells that frequentlycauses severe bone destruction and debilitating bone
pain, resulting in substantially diminished functional capacity
and quality of life.(1,2) Across a retrospective study, approxi-
mately 80% of all myeloma patients experienced pathological
fractures and 90% had osteolytic bone lesions over the course of
disease,(3) which correlates with poor survival and mortality.(4)
Myeloma-induced bone disease occurs via several mechanisms.
In most cases, osteoclast-stimulating factors including receptor
activator of NF-kB ligand (RANKL),(5,6) macrophage inﬂamma-
tory protein 1,(7,8) and various interleukins (IL-1b,(9) IL-3,(10) and
IL-6(11)) are produced by myeloma cells or tumor-activated cells
in the bone marrow microenvironment (BMME), causing an
increase in bone resorption. In addition, osteoblast inhibitors
such as dickkopf-1 (Dkk-1),(12,13) activin A,(14,15) and sclero-
stin(16,17) are upregulated in patient sera resulting in a decrease
in bone formation. Overall, this imbalance of bone remodeling
results in severe bone loss. Myeloma patients presenting with
bone disease are commonly prescribed the antiresorptive agent
zoledronic acid (Zol).(18) However, although Zol and other
antiresorptives are effective at inhibiting osteoclastic bone
resorption, they do virtually nothing to repair existing bone
damage and as a result, bone remains weak and at risk of
fracture.
Bone anabolic therapies using inhibitors of activin A(15) and
Dkk-1(19,20) have shown promise in preclinical models of
myeloma but thus far have resulted in only modest beneﬁt in
clinical trials(21–23) and have also led to some unexpected side
effects. For example, rises in hematocrit after treatment with
Sotatercept, a decoy receptor for activin A, have been observed,
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leading to a repurposing of this and similar agents as a
treatment for cancer-induced anaemia.(21) More recently,
deletion of the sclerostin gene (Sost) or administration of an
anti-sclerostin antibody prevented bone disease in murine
models of myeloma.(24) Furthermore, when an anti-sclerostin
treatment was used in combination with Zol in preclinical
models of myeloma, using a preventative regimen, they showed
superior effects on fracture resistance compared with Zol
alone.(25) However, sclerostin’s effectiveness on established
osteolytic bone disease has not yet been assessed in murine
models or in patients with myeloma. In osteoporotic patients,
anti-sclerostin therapy (Romosozumab) was associated with a
lower risk of fracture(26) but was also associated with potential
adverse cardiac events.(27) In addition, the positive effects of
anti-sclerostin therapy upon bone formation were only
sustained for a short period.(26) Furthermore, a combination of
Dkk-1 and sclerostin inhibition using a bi-speciﬁc antibody
approach demonstrated great promise at increasing bone
formation and bone strength in na€ıve rodents and therefore
would be a desirable method to test in preclinical models of
myeloma.(28)
As indicated, there is a clear demand for new bone anabolic
agents for patients with myeloma and established osteolytic
bone disease. It is hoped that such therapies will enhance bone
formation for sustained periods, leading to repair of damaged
bones. This has clear translational potential for substantially
improving the morbidity and quality of life in terms of fracture
risk, pain control, and functional status for patients with
myeloma bone disease.
A potential therapeutic target in myeloma is TGFb, which is
a cytokine reported to have both inhibitory(29,30) and
stimulatory(31,32) roles in bone formation. Speciﬁcally, it is
known to inhibit osteoblast differentiation. TGFb is also known
to be expressed by patient myeloma cells,(33,34) is upregulated
in sera from some monoclonal gammopathy of undetermined
signiﬁcance (MGUS) patients,(35) and is associated with
immunoparesis in myeloma patients at various stages of the
disease.(36) It has also been shown to be overexpressed by
bone marrow stromal cells (BMSC) from myeloma patients(34)
and is liberated from bone mineral matrix undergoing
resorption. TGFb’s actions can be blocked using a TGFbRI
inhibitor (SD-208) in vitro(37) and, more recently, TGFb
inhibition has been used as anti-tumor therapy in preclinical
models of myeloma,(38,39) breast cancer,(40–42) and prostate
cancer.(43) Interestingly, several of these inhibitors are now in
cancer clinical trials as anti-tumor drugs (e.g. NCT02452008
and NCT01401062(44,45)). However, TGFb inhibition has been
shown to have direct bone anabolic effects in na€ıve animals,
resulting in increased bone formation and bone integrity.(29)
This complements ﬁndings from immune-competent models
of myeloma where TGFb inhibition resulted in signiﬁcantly
higher vertebral strength and fewer femoral osteolytic lesions
compared with control mice.(46) Currently, no studies have
explored the efﬁcacy of bone anabolic therapy in combination
with an antiresorptive speciﬁcally to evaluate whether repair
of existing osteolytic lesions is possible (previous studies have
only focused on preventing the development of bone lesions
at the end stage of disease). Here we show that bone anabolic
therapy using an anti-TGFb (1D11) antibody combined with
the standard of care antiresorptive Zol are able to repair
existing osteolytic lesions and are more effective at repairing
osteolytic lesions and preventing myeloma bone disease than
either therapy alone.
Materials and Methods
Ethics statement
All procedures involving animals were conducted at the
University of Shefﬁeld (UK) and were approved by the Home
Ofﬁce (PPL 70/8799) and the University of Shefﬁeld’s Animal
Ethics Committee in accordance with the Animal (Scientiﬁc
Procedures) Act 1986.
Osteoblast isolation and differentiation
Primary calvarial osteoblast-like cells (Ob-LC) were isolated and
differentiated as described previously(47) using 4% FCS and BMP-
2 (30 ng/mL) (Bio-Techne, Abingdon, UK). To determine the
effect of TGFb upon osteoblast differentiation, Ob-LC were
cultured with either vehicle (CTRL), recombinant TGFb1
(rTGFb1) (5 ng/mL) and mouse IgG1 isotype control (IC)
antibody (25mg/mL) (Bio-Techne) (rTGFbþ IC), or rTGFb1
(5 ng/mL) and 1D11 antibody (25mg/mL) (Bio-Techne), (rTGFb
þ 1D11). Media was changed every 2 to 3 days and differentia-
tion was assessed at 7 and 14 days after treatment began by
examining alkaline phosphatase (Alp) and at 14 and 21 days
using alizarin red staining to detect mineralization, as described
previously.(48) Osteosarcoma SAOS-2 cells (ATCC, Teddington,
UK) were cultured as described previously,(49) treated as above
for 3 days, and cultured in 1% FCS to measure Alp. Each
experiment was repeated at least three times (n¼ 3) and
representative data are presented as a fold change.
Osteoclast assays
Bone marrow osteoclasts were isolated and cultured from 4-
week-old female BALB/c mice as previously described.(50) Cells
were then treated with either vehicle (CTRL), IC (25mg/mL), or
1D11 (25mg/mL) every 2 to 3 days for 14 days. Osteoclast
numbers and resorption area were then analyzed as previously
described.(50)
Myeloma cell viability assays
JJN3 and U266 humanmyeloma cell lines were cultured in RPMI-
1640 medium (containing 10% FCS, 1% penicillin/streptomycin,
100U/100mg/mL, 1% non-essential amino acids, and 1%
sodium pyruvate, 1mM) at 37°C in 5% CO2. Cells were seeded
(at 2 104 cells/well) in triplicate in 96-well plates and treated
with either vehicle (CTRL), IC (25mg/mL), or 1D11 (25mg/mL).
After 4 hours, 24 hours, 48 hours, and 72 hours, cell viability was
measured using an Alamar Blue assay (ThermoFisher, Warring-
ton, UK) according to the manufacturer’s instructions.
ELISA
ELISA was used to detect murine TRAP5b (Oxford Biosystems,
Oxford, UK), murine P1NP (Immuno Diagnostic Systems, Tyne &
Wear, UK), murine IL-6 (Abcam, Cambridge, UK), and human IgE
paraprotein (ThermoFisher) in murine sera following the
manufacturer’s instructions.
In vivo studies
Nod/Scid g (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were
purchased from Charles River Laboratories (UK). Animal
numbers were calculated using GPower software recom-
mended by NC3Rs. All animals were housed in the Biological
Service Unit at the University of Shefﬁeld in individual ventilated
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cages. Both an aggressivemyelomamodel using JJN3 cells and a
moderately aggressive model using U266 cells were used in the
in vivo experiments. In NSG mice, these cell types speciﬁcally
colonize the bone after intravenous (iv) injection with no
extramedullary growth resulting in bone disease as described
previously.(51–53)
The effect of 1D11 in na€ıve and JJN3-bearing NSG mice
Seven- to 8-week-old female NSG mice were randomized into
groups (n¼ 5/group) and injected iv via the tail vein with 100mL
PBS (Na€ıve) or 1 106 JJN3 cells (JJN3). After 7 days, mice were
treated with either 20mg/kg IgG1 IC (Na€ıveþ IC/ JJN3þ IC) or
20mg/kg 1D11 (Na€ıveþ 1D11/ JJN3þ 1D11) via intraperitoneal
(ip) injection every 3 days and mice were culled after 21 days
post-tumor cell injection.
Mouse group numbers were ascertained through the use of
the power calculation formula:
2ðSDÞ2  fða;bÞ=D2
where a (signiﬁcance level) was 0.05, b (power level) was 90%,
and both D (least practicable difference between groups) and
standard deviation were taken from a similar study with regard
to percentage trabecular bone volume (BV/TV, bone volume/
total volume). It gave rise to the following power calculation:
2 1:4ð Þ2  10:5=32 ¼ 4:6; i:e: 5 mice:
Assessment of tumor burden and bone disease (ex vivo)
At the end of the experiment, mice were euthanized and the
bone marrow from the left femora were ﬂushed and tumor
burden was assessed by anti-human leukocyte antigen (HLA)
staining analyzed by ﬂow cytometry using a FACS Calibur and
Cell Quest software (BD Biosciences San Jose, CA, USA) as
described previously.(54) Tumor burden was also quantiﬁed in
hematoxylin-stained parafﬁn-embedded sections, which were
scanned using a Hamamatsu Nanozoomer XR (Hamamatsu City,
Japan) and analyzed bymorphology as a percentage of the bone
marrow using Image Scope software (Leica Biosystems, Buffalo
Grove, IL, USA). To assess bone disease, after mouse euthanasia,
the right and left tibias were analyzed by mCT using a SkyScan
1272 ex vivo mCT scanner at 50 kilovolts (kV) and 200
microamperes (mA), using an aluminium ﬁlter of 0.5mm and
pixel size of 4.3mm2 as described previously.(19,51) BV/TV,
trabecular number, trabecular thickness, cortical thickness,
lesion area and lesion number parameters were then assessed
as described previously(51) and according to standard guide-
lines.(55) 3D models of trabecular bone were created using
ParaView Software (Clifton Park, NY, USA). Histomorphometry
was used to detect differences in osteoblast and osteoclast
numbers on longitudinal bone sections using Osteomeasure
software (Osteometrics, Decatur, GA, USA), as described
previously(51) and following standard guidelines.(56)
Efficacy of 1D11 and Zol combination therapy in the JJN3
murine model of MM
Eight- to 9-week-old female mice were randomized into groups
(n¼ 8/group) and treated as follows: group 1, PBS iv (Na€ıve);
group 2, 1 106 JJN3 cells iv and IC (20mg/kg IgG1, ip every
3 days post-tumor cell injection) (JJN3); group 3, JJN3 cells and
Zol (Procter & Gamble, 125mg/kg subcutaneously (sc) on
days 13 and 16 post-tumor cell injection) and IC (Zol); group
4, JJN3 cells and 1D11 (20mg/kg, ip every 3 days post-tumor cell
injection) (1D11); or group 5, JJN3 cells, Zol, and 1D11 (Combo).
After 21 days post-tumor cell injection, all animals were
euthanized. Tumor burden and bone disease were assessed as
described above. Murine P1NP, TRAP5b, and IL-6 serum levels
were quantiﬁed by ELISA as described above. Mouse group
numbers were determined using the same power calculation
formula shown above. a was taken as 0.05, b was taken as 90%,
andD and SD values were taken from the results of the “effect of
1D11 in na€ıve and JJN3-bearing NSG mice” study described
above with regard to percentage BV/TV. It gave rise to the
following power calculation:
2 1:8ð Þ2  10:5=32 ¼ 7:6; ie; 8 mice
Longitudinal monitoring of lesion repair after 1D11 and
Zol combination therapy in the U266 murine model of
myeloma
Twenty-two female NSGmice (7 to 8 weeks old) were injected iv
with 1 106 U266 cells. At 5 weeks post-tumor cell injection,
bone disease progression was monitored twice a week in the
right tibias of each mouse using a VivaCT 80 in vivo preclinical
mCT scanner (Scanco, Zurich, Switzerland) as described below.
Upon detection of established osteolytic lesions (at approxi-
mately 6 weeks post-U266 injection), mice were randomly split
into three groups and treated as follows: group 1, vehicle (U266);
group 2, Zol (125mg/kg sc, 3 days apart) and IC (20mg/kg IgG1,
ip, every 3 days) (Zol); or group 3, 1D11 (20mg/kg, ip every 3
days) and Zol (Combo). Mice were culled 3 weeks post-
treatment (group 1, n¼ 6; group 2, n¼ 8; and Group 3, n¼ 8)
and tumor burden was assessed by ﬂow cytometry (HLA
staining), histology (morphology), and ELISA (IgE paraprotein
levels) as described above.
Mouse group numbers were determined using the same
power calculation shown above:
2 1:8ð Þ2  10:5=32 ¼ 7:6; ie; 8 mice:
However, because of a smaller cohort than anticipated, only 6
mice were available for the vehicle group. This was deemed
acceptable because the vehicle group was less variable than the
treatment groups with regards to bone lesion development,
based on previously published data.(51)
Bone disease assessment (in vivo)
Mice were anesthetized and right tibias were scanned using a
VivaCT 80 at 45 kV and 177mA with a voxel size of 10.4mm on
week 0 (W0; when bone disease was ﬁrst detected after tumor
cell inoculation, at approximately 6 weeks) and then again after
3 weeks (W3). For image registration, W3 tibia data sets were
registered to their paired W0 control data sets using MIM
Maestro (v. 6.6.6, Cleveland, OH, USA). After registration, both
data sets were volumetrically registered using Drishti software
(v. 10, ANU Vizlab, Acton, Australia) and quantiﬁed using ImageJ
(version 1.47, NIH, Bethesda, MD, USA). The percentage change
in lesion area, cortical thickness, and BV/TV was then calculated
from time of disease onset (W0) to 3 weeks post-treatment (W3),
presented as the mean percentage change for each group. 3D
transverse models of the tibias were created using ParaView
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software and 3-D longitudinal models of the tibias were created
using Drishti software.
Statistical analysis
All data were analyzed using GraphPad Instat version 6.0b (La
Jolla, CA, USA). Where possible, the distribution of data was
analyzed using a D’Agostino-Pearson omnibus normalization
test and relevant parametric or nonparametric statistical tests
were used. If normalizationwas not possible, normal distribution
was assumed and data were analyzed using either a Student’s t
test or one-way ANOVAwith a Tukey’s multiple comparison test.
Where data was not normally distributed, a nonparametric
Kruskal-Wallis test followed by a Dunn’s multiple comparison
test was used. Any potential outliers were identiﬁed using
Grubb’s outlier analysis and removed accordingly. All data were
expressed with error bars representing mean standard devia-
tion (SD).
Data sharing
Data will be accessible to the public after publication via ORDA,
the University of Shefﬁeld’s Research Data Catalogue and
Repository. All data are preserved for 10 years and those
interested in obtaining access to these data must contact the
ﬁrst author via email.
Results
TGFb inhibition restores osteoblast differentiation in
vitro and has a bone anabolic effect in vivo
TGFb, as described above, is secreted by patient myeloma cells
and BMSC(34) and is also liberated from bone matrix upon
resorption.(57) Importantly, TGFb is also an inhibitor of osteo-
blast differentiation, thus contributing to the mechanism of
bone disease in myeloma patients. Therefore, we wanted to,
ﬁrst, conﬁrm that blocking TGFb using a monoclonal anti-TGFb
antibody (1D11) would prevent rTGFb1 inhibition of osteoblast
differentiation and, second, that 1D11 would result in a bone
anabolic effect in na€ıve and tumor-bearing mice.
Treatment of primary murine calvarial Ob-LC with rTGFb1
resulted in a 52% (p 0.001) and 58% (p 0.01) reduction in Alp
at 7 and 14 days, respectively, which was prevented upon
treatment with 1D11 at both time points (p 0.01) (Fig. 1A i–ii).
This effect was also observed using the human osteosarcoma
cell line SAOS-2 (Fig. 1A iii). In addition, rTGFb1 inhibited Ob-LC
mineralization by 89% at 14 days (p 0.01) and 88% at 21 days
(p 0.001); this was also prevented after treatment with 1D11
(p 0.01, p 0.001, respectively) (Fig. 1A iv–vi). This conﬁrmed
similar results reporting that TGFb prevents osteoblast differen-
tiation in MC3T3-E1, C2C12 cells, and primary BMSC from
myeloma patients, an effect that could be blocked by TGFb
inhibition.(39,58)
We then veriﬁed the translational efﬁcacy of this concept in
vivo by administering 1D11 into na€ıve mice and mice bearing
JJN3 myeloma cells (treatment schedule described in Fig. 1B).
1D11 treatment in vivo resulted in a signiﬁcant increase in BV/TV
in both na€ıve (130%) (p 0.01) and JJN3-bearing mice (183%)
(p 0.001) compared with IC-treated animals (Fig. 1C i–v). JJN3-
bearing mice treated with 1D11 also had a higher trabecular
number (Fig. 1C vi) (p 0.01), whereas na€ıve, but not JJN3-
bearing, mice treated with 1D11 had thicker trabeculae (Fig. 1C
vii) (p 0.01). These data conﬁrmed previous reports that 1D11
was a bone anabolic agent in na€ıve mice(29) and prevented
trabecular bone loss in immune-competent myeloma-bearing
animals.(46)
TGFb inhibition (1D11) in combination with Zol
significantly increased trabecular bone volume
compared with monotherapy with either agent in the
JJN3 model of myeloma
Because 1D11 promoted bone formation in na€ıvemice (Fig. 1C i–
ii) and prevented bone loss in JJN3-bearing mice (Fig. 1C iii–iv),
we investigated whether administration with the antiresorptive
Zol would further enhance the bone anabolic effect of 1D11 in
the JJN3 model of myeloma (treatment schedule described in
Fig. 2A). Zol alone signiﬁcantly increased BV/TV (p 0.01)
compared with tumor control (Fig. 2B i–ii, v) (conﬁrming
previous ﬁndings(51)). Similarly, 1D11 prevented bone loss
compared with the tumor control group (Fig. 2B i, iii, v),
conﬁrming our previous data (Fig. 1C iii–v). Most interestingly,
when Zol and 1D11 were given in combination, BV/TV was 48%
higher (p 0.001) compared with Zol (Fig. 2B ii, iv, v) and 65%
higher (p 0.0001) compared with 1D11 alone (Fig. 2B iii, iv, v).
The trabecular number was also signiﬁcantly higher in the
combination group compared with Zol alone (Fig. 2B vi)
(p 0.001), whereas there were no signiﬁcant changes in
thickness of the trabeculae between the Zol, 1D11, or the
combination groups (Fig. 2B vii). In contrast to trabecular bone,
cortical bone thickness was comparable between na€ıve and
JJN3-bearingmice (Fig. 2C v), indicating JJN3 tumor cells did not
cause signiﬁcant loss of cortical bone. Zol and 1D11 mono-
therapies had no effect on cortical thickness compared with
vehicle controls. However, cortical thickness was higher in mice
receiving combination therapy compared with 1D11 alone
(Fig. 2C iii, iv, v). Analysis of osteolytic lesions in the cortical bone
revealed vehicle-treated JJN3-bearing mice had an average of
26 13.8 lesions in the area analyzed (Fig. 2C vi), and 1D11
monotherapy had no effect on lesion number or size compared
with the JJN3 with vehicle (Fig. 2C vi, vii). In comparison,
administration of Zol over 2 weeks was highly effective at
preventing osteolytic lesion development in mice, with only
4 1.9 lesions present (Fig. 2C vi). Similarly, mice treated with
Zol and 1D11 in combination had virtually no cortical bone
lesions, with only 2 2.5 lesions per mouse in the area analyzed
(Fig. 2C vi). Although osteolytic lesion number and size were
slightly lower in mice treated with the combination compared
with Zol treatment alone, this was not signiﬁcant because Zol
treatment alone prevented the development of virtually all
lesions in mice.
Overall, this study clearly shows that TGFb inhibition therapy
when combined with Zol was more effective at preventing
trabecular bone loss than either monotherapy alone in an
aggressive murine model of myeloma.
To determine whether these observations were mediated via
a bone anabolic or antiresorptive effect, histological analysis was
conducted by quantifying osteoblast and osteoclast numbers on
endocortical and trabecular bone surfaces in the primary
spongiosa. Unexpectedly, when osteoblast numbers were
analyzed, there were no signiﬁcant differences between any
of the tumor groups looking at the end stage of disease (Fig. 3A
i–x). However, 1D11 treatment did result in fewer osteoclasts on
endocortical bone surfaces (42%) (p  0.05) and in the primary
spongiosa region (47%) (p 0.0001) (Fig. 3A i, iii, v, vii, xi, xii),
which was more pronounced with Zol treatment and resulted in
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Fig. 1. Administration of anti-TGFb (1D11) prevented rTGFb inhibition of osteoblastic alkaline phosphatase production andmineralization in
vitro and resulted in a substantial bone anabolic effect in vivo. (A) Alp production in primarymurineOb-LC cultured in osteogenicmediawith vehicle
(CTRL), rTGFb and IC antibody (rTGFbþ IC), or rTGFb and 1D11 antibody (rTGFbþ 1D11) for 7 (i) and 14 days (ii). Alp production in SAOS-2 cells cultured
in standard media and treated as above for 3 days (iii). Mineralization in Ob-LC treated as above for 14 (iv) and 21 days (v). Representative images
of mineralization in Ob-LC treated as above (vi). All data are representative from four independent experiments, presented as mean fold change SD,
one-way ANOVA, p 0.01, p 0.001, and p 0.0001. (B) Schematic demonstrating the treatment schedule for 1D11monotherapy treatment in
Na€ıvemice and the JJN3model of myeloma. (C) Representative 3D trabecularmCT images from the tibias of Na€ıveþ IC (i), Na€ıveþ 1D11 (ii), JJN3þ IC (iii),
and JJN3þ 1D11 (iv) mice. BV/TV (v), trabecular number (vi), and trabecular thickness (vii) analyzed in the tibias by mCT. All data are presented as
mean SD, Student’s t test, p  0.001 and p  0.001.
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Fig. 2. Administration of anti-TGFb (1D11) in combination with Zol signiﬁcantly increased BV/TV compared with monotherapy in the JJN3
model of myeloma. (A) Schematic demonstrating the treatment schedule for Zol or 1D11 monotherapies or in combination in the JJN3 model of
myeloma. (B) Representative 3D trabecular bone mCT images from the tibias of JJN3þ vehicle (JJN3) (i), JJN3þZol (Zol) (ii), JJN3þ 1D11 (1D11) (iii), and
JJN3þ 1D11þZol (Combo) (iv) mice. BV/TV (v), trabecular number (vi), and trabecular thickness (vii) analyzed in the tibias bymCT. (C) Representative 3D
transverse cortical and trabecular bonemCT images from the tibias of JJN3 (i), Zol (ii), 1D11 (iii), and Combo (iv) mice; blue arrows show areas of bone loss
and green arrows show areas of new bone formation. Cortical thickness (v), lesion number (vi), and lesion area (vii) analyzed in the tibias by mCT. All data
are presented as mean SD, one-way ANOVA and Tukey’s multiple comparison test, p  0.05, p  0.01, p  0.001, and p  0.0001.
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Fig. 3. Zol and 1D11 combination therapy did not signiﬁcantly increase bone formation or decrease bone resorption compared with
monotherapies in the JJN3model ofmyeloma. (A) Representative histological images of tibia sections from JJN3-bearingmice treatedwith IC (i, v), Zol
(ii, vi), 1D11 (iii, vii), and Combo (iv, viii), at20 magniﬁcation (i–iv) and40 magniﬁcation (v–viii) showing tumor bone marrow (TBM) and cortical bone
(CB). Number of osteoblasts on the endocortical surface (ix) and on the bone primary spongiosa (x). Number of TRAP-positive osteoclasts on the
endocortical surface (xi) and on the primary spongiosa (xii). (B) Murine TRAP5b (i) present in murine sera when detected by sandwich ELISA. Primary
murine osteoclast numbers (ii) and resorption area (iii) after treatment with vehicle (CTRL), IC, or 1D11 after 3 days. Murine P1NP (iv) and murine IL-6 (v)
present in murine sera when detected by sandwich ELISA. All data are presented as mean SD, one-way ANOVA, p 0.05, p 0.01, p 0.001 and
p  0.0001.
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even fewer osteoclasts on the endocortical surface (85%) (p 
0.0001) and primary spongiosa (88%) (p 0.0001) compared
with JJN3 IC-treated animals (Fig. 3A i, ii, v, vi, xi, xii). In mice
receiving combination treatment, trabecular and endocortical
osteoclast numbers were comparable to monotherapy of Zol
with no further reduction in osteoclast numbers (Fig. 3A ii, iv, vi,
viii, xi, xii), although because Zol alone reduced osteoclast
numbers to effectively zero, it is impossible to ascertain whether
therewould have been a further reductionwith the combination
treatment. To further investigate the effect of combination
therapy on bone resorption and formation, systemic analysis of
bone turnover markers TRAP5b and P1NP in mouse sera were
also conducted at the end stage of disease. TRAP5b concen-
trations in Zol-treated animals correlated with the histological
osteoclast data, whereby Zol alone signiﬁcantly reduced TRAP5b
levels compared with tumor (p  0.05), but this was not
observed in the 1D11 alone group (Fig. 3B i). Therefore, we
assessed the effects of 1D11 on primary murine osteoclasts in
vitro and observed a signiﬁcant reduction in their numbers
(Fig. 3B ii) and resorption area (Fig. 3B iii) comparedwith controls
(vehicle and IC). However, despite this, TRAP5b serum levels in
the in vivo study were not further reduced in the combination
treatment group comparedwith Zol alone, whichwas consistent
with the histological osteoclast data. P1NP levels also correlated
with the histological osteoblast data, where at the end stage of
disease, circulating levels were unchanged between all groups
(Fig. 3B iv).
We sought to understand why osteoclast numbers were
decreased by ID11 treatment and chose to investigate the role of
IL-6. Previously, IL-6 has been shown to be upregulated in
myeloma patient sera(59) and by BMSC, particularly when in
contact with myeloma cells,(57) and IL-6 is thought to increase
the proliferation/differentiation of osteoclasts.(60) TGFb is also
known to upregulate the production of IL-6 by BMSC, the effect
of which can be blocked using a TGFb signaling antagonist (SD-
208, a small molecule inhibitor).(37) Therefore, TGFb in myeloma
is also likely to contribute to bone disease by upregulation of IL-
6 in the BMME. Consequently, we investigated IL-6 in the sera of
mice at the end stage of disease and found that IL-6 levels were
unchanged in tumor control or Zol-treated mice, but were
signiﬁcantly reduced in mice treated with either 1D11 alone or
1D11 in combination with Zol (p  0.05 and p  0.001,
respectively) (Fig. 3B v). It is therefore suggested that this IL-6
reduction was speciﬁc to the 1D11 treatment with no additive or
synergistic effect with Zol.
Overall, using the JJN3 model of MM, combination therapy
showed a clear additive effect upon increasing trabecular bone.
However, limitations of this 3-week model of myeloma, ie, the
rapidly progressive osteolytic phenotype, made it difﬁcult to
identify if combination therapy was more effective than
monotherapy at protecting against or repairing myeloma
bone disease in the cortical bone. We therefore chose to
investigate the effects of combination therapy in the U266
model of myeloma, which also features a marked destructive
bone phenotype but develops less quickly over a more
protracted period (after 6 to 9 weeks post-tumor cell injection).
Established U266-induced osteolytic lesions are repaired
with combined TGFb inhibition (1D11) and Zol therapy
To determine whether anti-TGFb therapy was capable of
repairing existing osteolytic bone lesions in tumor-bearing
mice, wemonitored changes to bone over time in the samemice
using in vivo mCT. The U266 murine model of myeloma is less
aggressive than the JJN3 model used above, whereby osteolytic
bone lesions in U266-bearing mice typically evolve more slowly
and can take up to 5 to 6 weeks to develop (treatment schedule
described in Fig. 4A). Bone disease on 3D transverse (Fig. 4B) and
longitudinal (Fig. 4C) mCT models was apparent from 6 weeks
post-tumor cell injection (W0) (Fig. 4B i, iii, v; Fig. 4C i, iii, v, blue
arrows) and became progressively worse over the subsequent
3 weeks (W3) (Fig. 4B ii; Fig. 4C ii, pink arrows). U266-bearing
mice treated with Zol alone, however, had areas of both
progressive lesion development (Fig. 4B iii, iv; Fig. 4C iii, iv, pink
arrows) and lesion repair byW3 (Fig. 4B iii-iv, green arrows). Most
strikingly, the Zol and 1D11 combination group did not show
progressive bone disease, and the initial regions of bone loss
were substantially repaired by week 3 (Fig. 4B v, vi; Fig. 4C v, vi,
green arrows). When quantiﬁed, there was a signiﬁcant decrease
in lesion area in the combination group compared with the Zol
alone (Fig. 4C vii) (p  0.05) and vehicle (p  0.05) groups.
However, when overall cortical thickness and BV/TV were
analyzed in this model, these parameters were not signiﬁcantly
different between the Zol alone and combination group but
were signiﬁcantly increased compared with the U266 vehicle
group (p  0.05, Fig. 4B viii, ix).
To explore the mechanism of this repair, we conducted
histomorphometric and serum bone turnover marker analysis.
Similar to the data acquired in the JJN3 combination study
(Fig. 3), U266-bearing mice treated with Zol alone or with the
combination group effectively reduced the numbers of
osteoclasts by 64% (p  0.0001) and 66% (p  0.0001),
respectively, on the endocortical surface compared with the
U266 vehicle group (Fig. 5 i–vii). In addition, osteoclasts were
signiﬁcantly reduced in the primary spongiosa by 54% (p 0.05)
in the Zol group and 51% (p  0.05) in the combination group
comparedwith the U266 vehicle group (Fig. 5 viii). TRAP5b levels
also correlated with histomorphometric analysis, whereby Zol
alone and in combinationwith 1D11 reduced TRAP5b compared
with the U266 vehicle group over time, but there were no
differences observed between the Zol alone and the combina-
tion groups (Fig. 5 ix). Surprisingly, there were no visible
osteoblasts on either of these surfaces in any of the groups,
despite the obvious repair in cortical bone lesions. Similarly,
there were also no differences in the serum P1NP levels between
the groups (Fig. 5 x), suggesting the level of bone formation
required to repair the lytic lesions was not high enough to
increase systemic P1NP levels.
Overall, these data strongly demonstrate that combination
therapy using TGFb inhibition with Zol can repair existing
osteolytic lesions in murine models of myeloma, a novel ﬁnding
not yet reported in myeloma or other cancer-induced bone
diseases.
TGFb inhibition in combination with Zol does not alter
JJN3 or U266 tumor burden in vivo
Because others have reported that TGFb inhibition has an anti-
tumor effect in vivo in models of breast cancer and
myeloma,(39–41) we wanted to discount that any effect we
observed was due to a reduction in tumor burden. Therefore, we
quantiﬁed localized tumor burden in the JJN3 and U266 models
by ﬂow cytometry (Fig. 6A i–ix) and histological morphology
(Fig. 6B i–vi). In addition, in the U266 model, we quantiﬁed
systemic human IgE paraprotein by ELISA (Fig. 6B vii). By all
methods and in both models assessed, Zol or 1D11
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Fig. 4. Zol and 1D11 combination therapy repaired osteolytic bone lesions in the U266murinemodel of myeloma. (A) Schematic demonstrating
the treatment schedule for Zol monotherapy or Zol and 1D11 combined (Combo) in the U266 model of myeloma. (B) W0: Time of bone disease
presentation (approximately 6 weeks post-U266 injection). W3: 3 weeks after treatment. Representative 3D transverse cortical and trabecular registered
in vivomCT images from the tibias of U266 vehicle W0 (U266W0) (i), U266 vehicle W3 (U266W3) (ii), U266þZol W0 (Zol W0) (iii), U266þZol W3 (Zol W3)
(iv), U266þComboW0 (ComboW0) (v), and U266þComboW3 (ComboW3) (vi) mice. (C) Representative longitudinal in vivomCT images from the tibias
of U266 W0 (i), U266 W3 (ii), Zol W0 (iii), Zol W3 (iv), Combo W0 (v), and Combo W3 (vi) mice. Blue arrows represent initial bone disease, pink arrows
represent progressive bone disease, and green arrows represent a reduction in bone disease and lesion repair. Percentage change in lesion area (vii) from
W0 to W3 by in vivo mCT, after image registration. Percentage change in cortical thickness (viii) fromW0 to W3 by in vivo mCT. Percentage change in BV/
TV (ix) fromW0 toW3 by in vivomCT. All data are presented asmean SD, Kruskal-Wallis and Dunn’s multiple comparison tests, p 0.05 and p 0.01.
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monotherapies or in combination had no signiﬁcant effect upon
tumor burden. Therefore, this indicates that all bone effects
observed in our studies were a direct effect upon bone itself and
not as a result of reduced tumor burden. To conﬁrm this, we also
treated JJN3 and U266 cells in vitro with vehicle, IC, or 1D11, and
no signiﬁcant effects on cell viability for either cell line were
observed (Fig. 6 viii, ix).
Discussion
Multiple myeloma remains a largely incurable bone marrow
cancer, which causes devastating bone disease resulting in a
substantially diminished quality of life for most patients. The
current standard of care for bone disease is antiresorptive
therapy, usually the bisphosphonate Zol. However, antiresorp-
tive therapy alone does not repair existing bone damage,
meaning bones remain weak and are prone to fracture.
Previously, bone anabolic therapy using parathyroid hormone
(PTH) or anti-sclerostin (Romosuzumab) showed improved bone
outcomes in patients with metabolic disorders such as
osteoporosis.(20,61–63) In addition, anti-sclerostin therapy in
preclinical models of myeloma using preventative treatment
strategies have inhibited bone loss and increased bone
strength,(25,63) highlighting that bone anabolic therapy could
be of great beneﬁt to patients with myeloma bone disease.
In the studies presented here, we have shown for the ﬁrst time
that the bone anabolic 1D11 (anti-TGFb antibody), when
administered in combination with the antiresorptive Zol,
provided a therapeutic strategy for both the prevention and,
more importantly, in the treatment of myeloma-induced bone
disease. We ﬁrst veriﬁed that rTGFb inhibited osteoblast
differentiation as shown previously(39,58,64) and that this could
be prevented using 1D11, which correlated with previous in
vitro osteoblast assays using TGFb small molecule inhibitors.(39)
In addition, we showed that 1D11 alone increased BV/TV in na€ıve
NSG mice, supporting data by Edwards and colleagues,(29) who
looked at the effect in C57BL/6 na€ıve mice, and 1D11
monotherapy also prevented bone loss in the JJN3 model of
myeloma, which corresponded with previous studies using the
5TGM1 model of myeloma.(46) Most importantly, we found that
when 1D11 was administered in combination with Zol, this
therapeutic strategy signiﬁcantly enhanced BV/TV in the JJN3
model of myeloma and treated bone disease and repaired
osteolytic lesions in the U266 model of myeloma, a ﬁnding not
yet reported in the literature. In addition, this effect was not
mediated by a reduction in tumor burden, which did not alter
after 1D11/combination treatment groups, consistent with
other ﬁndings in myeloma.(46) However, this lack of effect
upon tumor burden is somewhat contradictory to some other
studies in myeloma(38,39) and breast cancer models,(65,66) which
did observe an anti-tumor effect. To conﬁrm whether 1D11 had
a direct anti-tumor effect on JJN3 or U266 cells, we treated them
with 1D11 in vitro and observed no effect on cell viability for
either cell line. Therefore, 1D11 does not directly inﬂuence
tumor growth in vitro or in vivo, and these discrepancies with
previous studies in anti-tumor effects may be due differential
regulation of factors implicated in tumor cell proliferation,
including PTHrP,(41) IL-6,(37) or Notch,(67) that are controlled by
TGFb signaling, which may vary between tumor cell types and
mouse strains. In addition, others have observed that the anti-
tumor effects of 1D11 may be dependent on the tumor
location,(68) the presence of other cells,(68–70) disruption of key
Fig. 5. Zol and 1D11 combination therapy did not signiﬁcantly decrease bone resorption or increase bone formation compared to monotherapy in the
U266model ofmyeloma. Representative histological images of tibias fromU266-bearingmice treatedwith IC (U266) (i, iv), Zol (ii, v), and Combo (iii, vi), at
20 magniﬁcation (i–iii) and 40 magniﬁcation (iv–vi). (vii) Number of TRAP-positive osteoclasts on the endocortical surface and (viii) on primary
spongiosa. (ix) Murine TRAP5b and (x)murine P1NP present inmurine sera detected by sandwich ELISA. All data are presented asmean SD, ANOVA and
Tukey’s multiple comparison, p  0.05 and p  0.0001.
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Fig. 6. 1D11 did not inhibit the growth of JJN3 or U266 cells in vivo or in vitro. (A) Representative ﬂow cytometry dot plots showing HLA-positive
tumor cells from femora bonemarrow ﬂushes from JJN3-bearing (i–iv) or U266-bearingmice (vi–viii) treated with IC (JJN3 or U266) (i, vi), Zol (ii, vii), 1D11
(iii), or Combo (iv, viii), quantiﬁed as a percentage of tumor burden (v, ix). (B) Representative parafﬁn-embedded hematoxylin-stained bone marrow
sections taken from Na€ıve (i 2, iii 40) or JJN3/U266-bearing mice (ii 2, iv 40) demonstrating how percentage of tumor area is quantiﬁed using
Image Scope software, normalmarrow circled in black (i), bone area in circled green (i, ii), tumor area circled in red (ii). Quantiﬁcation of histological tumor
burden in parafﬁn-embedded tibia sections taken from JJN3-bearing mice (v) or U266-bearing mice (vi) and treated with IC, Zol, 1D11, or Combo,
quantiﬁed using Image Scope Software, as shown above, displayed as a percentage of tumor in the bone marrow compared with normal marrow. IgE
paraprotein present in the sera of U266-bearing mice at the end stage of disease, treated with IC, Zol, or Combo and analyzed by ELISA (vii). In vitro
culture of JJN3 (viii) and U266 (ix) cells treated with vehicle (CRTL), IC, or 1D11 for 4 hours, 24 hours, 48 hours, and 72 hours. All data are presented as
mean SD.
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signaling pathways,(71) and when 1D11 treatment commen-
ces.(69) Therefore, there are potentially a number of reasons why
we did not observe an anti-tumor effect in our in vivo studies.
A potential limitation of our studies is they were all performed
in immunocompromised mice. However, the rationale for using
these models was based on the marked destructive osteolytic
bone lesions that both JJN3 and U266 models feature(51)
compared with the immune-competent 5TGM1 model, which
has a less pronounced bone disease.(72) In addition, to monitor
lesion repair, a larger therapeutic window was required from
onset of established osteolytic lesions to the end stage of
disease. In the 5TGM1 model, this is only a few days (17 to
21 days post-5TGM1 cell injection),(72) whereas in the U266
model used here, it was for approximately 3 weeks (6 to 9 weeks
post-U266 cell injection). Therefore, this provided us with a
larger treatment window to clearly determine the effects of
combined 1D11 and Zol treatment on bone repair. In addition,
Zol and 1D11 (as well as SD-208, a small inhibitor to TGFb
receptor type 1) have previously been used in immune-
competent mice. For example, Edwards and colleagues(29)
have assessed 1D11 in na€ıvemice, and Nyman and colleagues(46)
have assessed 1D11 in the 5TGM1 model. Similarly, we have
previously assessed the effects of Zol in immunocompromised
mice(51,73) and shown similar effects on bone to immune-
competent mice.(74) Therefore, we would expect to observe
similar effects on bone in immune-competent animals treated
with combined 1D11 and Zol.
Our studies clearly demonstrate the beneﬁts of combined
1D11 and Zol treatment on bone, yet the exact mechanism by
which the repair of bone occurs remains unclear. Monotherapy
of Zol or 1D11 in the JJN3model of MM resulted in a reduction in
osteoclasts, consistent with previous ﬁndings by Mohammed
and colleagues(75) and Edwards and colleagues(29) using SD-208/
1D11 in na€ıve mice. In the 1D11 monotherapy group, this was
potentially mediated by a reduction in IL-6 levels, a ﬁnding
described previously when SD-208 blocked TGFb1-induced
secretion of IL-6 by BMSC in vitro.(39) Nevertheless, in our in vivo
studies we were unable to identify an increase in osteoblast
numbers or P1NP sera levels (markers of bone formation),
despite clear enhancement of bone formation. We suspect that
this may be because our euthanization time points did not
coincide with the precise time points at which osteoblast
numbers, or biomarker levels, were increased, as well as lack of
sensitivity in the sera analysis. In addition, when early and late
osteocyte patterns were examined by anti-sclerostin and anti-
E11 immunohistochemical staining, no differences were found
after 1D11 treatment (data not shown), and sclerostin sera levels
were also unchanged between the groups (data not shown),
highlighting that there were no signiﬁcant changes in
osteocytes after 1D11 treatment. Studies by Nyman and
colleagues(46) did observe an increase in osteoblasts after
TGFb inhibition, but their studies differed to ours inmouse strain
(C57BL/KalwRij), cell line (5TGM1), and inhibitor (SD-208), which
could have affected the osteoblast analysis. Therefore, we
strongly believe that the additive effect observed in both
myeloma models is due to both an inhibitory effect on
osteoclasts and a substantial anabolic effect on osteoblastic
bone formation. The latter is likely to have occurred early after
treatment and thus has not been captured at the end stage of
disease when tumor burden is high.
Nevertheless, the overall ﬁndings described here show a
highly translational approach for the use of bone anabolic and
antiresorptive therapy to prevent and repair myeloma-induced
bone disease, particularly as anti-TGFb therapy using a
humanized antibody (GC1008) is currently in clinical trials in
breast cancer (NCT01401062).(44,45) Furthermore, we are now
exploring the optimum sequencing approach of bone anabolic
and antiresorptive therapies, given promising data emerging
from clinical trials in patients with osteoporosis.(76,77) We
strongly believe that combination therapy delivered in the
optimum sequence has the potential to substantially improve
patient prognosis by reducing fracture risk, reducing pain,
increasing functional status, and thus providing a very
considerable overall improvement in quality of life for those
with this devastating aspect of myeloma.
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